Published in N Engl J Med on March 14, 1996
Anticoagulation therapy for venous thromboembolism. MedGenMed (2004) 3.61
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21
The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin. BMJ (1998) 2.13
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost (2012) 2.09
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71
Early discharge hospital at home. Cochrane Database Syst Rev (2009) 1.67
Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data. CMAJ (2009) 1.58
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Diagnosis and treatment of deep-vein thrombosis. CMAJ (2006) 1.44
Anticoagulants for venous thrombosis. Postgrad Med J (1997) 1.39
Deep vein thrombosis and air travel: record linkage study. BMJ (2003) 1.34
Current use of the A&E ward. J Accid Emerg Med (1997) 1.07
Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis. N Engl J Med (1996) 1.05
Beyond evidence: the micropolitics of improvement. BMJ Qual Saf (2011) 1.04
Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood (2006) 1.03
Survey of primary care physicians and home care clinicians. J Gen Intern Med (2002) 1.01
Outpatient management of deep vein thrombosis. J Accid Emerg Med (1998) 0.99
Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol (2010) 0.98
Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med (2014) 0.98
Home visits. An access to care issue for the 21st century. Can Fam Physician (2000) 0.95
Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ (2001) 0.94
Is routine thromboprophylaxis justified among Indian patients sustaining major orthopedic trauma? A systematic review. Indian J Orthop (2011) 0.93
Treatment of deep vein thrombosis: what factors determine appropriate treatment? Can Fam Physician (2005) 0.92
Deep Venous Thrombosis and Pulmonary Embolism. Curr Treat Options Cardiovasc Med (2002) 0.90
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ (1998) 0.87
Upper extremity deep vein thrombosis. Int J Crit Illn Inj Sci (2012) 0.87
Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci (2001) 0.86
Post-discharge symptomatic thromboembolic events in hip fracture patients. Ann R Coll Surg Engl (2007) 0.85
Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg (2000) 0.83
Optional inferior vena caval filters: where are we now? Eur Radiol (2008) 0.83
Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med (2000) 0.82
Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis. Ann Med Surg (Lond) (2017) 0.82
Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review. PLoS One (2012) 0.81
Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81
High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop Relat Res (2009) 0.81
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J (2011) 0.80
Effect of a low molecular weight heparin molecule, dalteparin, on cellular apoptosis and inflammatory process in an incisional wound-healing model. Surg Today (2007) 0.79
Paget-Schrotter syndrome and complications of management. BMJ Case Rep (2013) 0.79
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag (2009) 0.78
Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb J (2005) 0.78
Management of venous thromboembolism: why not treat it at home? Can Fam Physician (2005) 0.78
Management of venous thromboembolism: an update. Thromb J (2016) 0.78
The new heparins. Ochsner J (2002) 0.76
Routine home treatment of deep vein thrombosis. BMJ (2001) 0.76
Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009). Thromb Res (2015) 0.75
Recent changes: pulmonary medicine. BMJ (1999) 0.75
Treatment of deep venous thrombosis with low molecular weight heparins. West J Med (1998) 0.75
Anticoagulation in patients with thromboembolic disease. Thorax (2001) 0.75
Preparation, Properties and Preclinical Pharmacokinetics of Low Molecular Weight Heparin-modified Isoliquiritigenin-loaded Solid Lipid Nanoparticle. Iran J Pharm Res (2016) 0.75
The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management. Saudi Med J (2015) 0.75
The Perioperative Management of Antithrombotic Therapies Using Enoxaparin. J Korean Med Sci (2017) 0.75
Massive hypercoagulable state despite full-dose anticoagulant treatment in a patient with occult malignancy: considerations concerning chemotherapy without definitive diagnosis. BMJ Case Rep (2010) 0.75
Pharmacologic prophylaxis and treatment of venous thromboembolism after knee arthroplasty. Sultan Qaboos Univ Med J (2007) 0.75
Diagnosis and treatment of deep vein thrombosis. West J Med (2000) 0.75
Low-molecular-weight heparins in the treatment of venous thromboembolism. Curr Control Trials Cardiovasc Med (2000) 0.75
Clinical uses for low-molecular-weight heparins. West J Med (1996) 0.75
Medical management of venous thromboembolic disease. Ochsner J (2000) 0.75
Low-molecular-weight heparin in the treatment of deep venous thrombosis. West J Med (1998) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Unfractionated versus low-molecular-weight heparin for deep venous thrombosis. N Engl J Med (1996) 0.75
Unfractionated versus low-molecular-weight heparin for deep venous thrombosis. N Engl J Med (1996) 0.75
Monitoring of anticoagulant therapy in heart disease: considerations for the current assays. J Tehran Heart Cent (2010) 0.75
A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital. Indian J Pharmacol (2015) 0.75
The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75
Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases. Tex Heart Inst J (1997) 0.75
Arrive: A retrospective registry of Indian patients with venous thromboembolism. Indian J Crit Care Med (2016) 0.75
Cost-Effectiveness Analysis of Treatment Acute Deep Vein Thrombosis in Clinic of Vascular Surgery Sarajevo. Open Access Maced J Med Sci (2017) 0.75
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
The Children's Depression, Inventory (CDI). Psychopharmacol Bull (1985) 11.73
Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol (1979) 8.44
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med (1999) 6.88
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen (2000) 6.24
Rating scales to assess depression in school-aged children. Acta Paedopsychiatr (1981) 6.19
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut (1965) 4.56
The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell (1989) 4.48
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci U S A (1990) 4.13
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. Br J Surg (2012) 4.01
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet (2001) 3.69
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
Management of women with mild and moderate cervical dyskaryosis. BMJ (1994) 3.65
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry (1985) 3.57
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science (1987) 3.29
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut (2010) 3.24
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol (1997) 3.06
Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci U S A (1997) 3.04
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2.97
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell (1990) 2.95
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Classification of suicidal behaviors: I. Quantifying intent and medical lethality. Am J Psychiatry (1975) 2.89
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell (1993) 2.73
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol (1987) 2.65
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Prohead and DNA-gp3-dependent ATPase activity of the DNA packaging protein gp16 of bacteriophage phi 29. J Mol Biol (1987) 2.59
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost (2006) 2.57
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 2.54
Retained surgical swabs in 13 dogs. Vet Rec (2011) 2.54
Cloning determinants of pathogenesis from Pseudomonas syringae pathovar syringae. Proc Natl Acad Sci U S A (1985) 2.50
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44